ALX Oncology Holdings (ALXO) has shared an announcement.
ALX Oncology Holdings Inc. is navigating changes to its Board of Directors following the immediate resignations of Jack Nielsen for health reasons and Itziar Canamasas, who accepted a new job incompatible with her Board duties. Scott Garland has been reclassified from a Class III to a Class II director, with his term now ending in 2025. Meanwhile, the Board, maintaining its compliance with Nasdaq’s majority independent director requirement, is actively searching for replacements and has restructured its committees, ensuring that all members, including Garland, meet the necessary independence and financial literacy standards.
For a thorough assessment of ALXO stock, go to TipRanks’ Stock Analysis page.
